Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 251Neoplasms 175Prostatic Neoplasms 146Colorectal Neoplasms 108Lung Neoplasms 99Leukemia, Myeloid, Acute 77Pancreatic Neoplasms 76Carcinoma, Non-Small-Cell Lung 69Multiple Myeloma 67Brain Neoplasms 65Melanoma 55Precursor Cell Lymphoblastic Leukemia-Lymphoma 54Ovarian Neoplasms 53Glioblastoma 50Head and Neck Neoplasms 49Uterine Cervical Neoplasms 48Neoplasm Metastasis 48Carcinoma, Hepatocellular 48Recurrence 41Sarcoma 39Hematologic Neoplasms 39Glioma 39Endometrial Neoplasms 37Carcinoma, Renal Cell 37Squamous Cell Carcinoma of Head and Neck 36Lymphoma, Non-Hodgkin 36Stomach Neoplasms 35Rectal Neoplasms 35Lymphoma 34Leukemia 34

Interventions

enfortumab vedotin 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Penile Neoplasms × 30 days × Clear all
NCT06104618 2026-06-08

Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis

Mayo Clinic

Phase 2 Recruiting
28 enrolled
Genitourinary

Penile Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡